This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Langstein, H. N. Articles by Norton, J. A. Search for Related Content PubMed PubMed Citation Articles by Langstein, H. N. Articles by Norton, J. A.

The Roles of -Interferon and Tumor Necrosis Factor in an Experimental Rat Model of Cancer Cachexia¹

Surgical Metabolism Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892

Administration of repetitive sublethal doses of either recombinant human tumor necrosis factor (TNF) or recombinant murine -interferon (IFN) to non-tumor-bearing (NTB) rats caused a significant decline in food intake and body weight. After 3 days rats became resistant to the anorectic and weight loss effects of TNF but maintained persistent diminished food intake and diminished body weight gain while receiving recombinant murine IFN. Passive immunization against recombinant rat -interferon allowed cachectic tumor-bearing (TB) rats to eat more food, have a lesser decline in body weight, live longer, and tolerate larger tumors than similar TB rats given nonspecific control antibody. TB rats treated with an antisera to recombinant murine TNF, which was 100% protective when given to NTB rats 6 h before a lethal endotoxin challenge, did not differ significantly from TB rats treated with control antibody with respect to food intake, body weight, survival, or tumor size. Serum levels of TNF or IFN were not detectable in cachectic tumor-bearing rats. The data indicate that the administration of exogenous IFN can simulate cachexia in NTB rats and that passive immunization against it can partially reverse the cachectic changes associated with cancer and prolong survival. These findings suggest that -interferon may be an important mediator of cachexia in this rat tumor model.

¹ Presented in part at the American College of Surgeons Meeting, Atlanta, GA, October 1989.

² To whom requests for reprints should be addressed, at Surgical Metabolism Section, Surgery Branch, National Cancer Institute/NIH, Building 10, Room 2B07, Bethesda, MD 20892.

Received 7/12/90. Accepted 2/22/91.

This article has been cited by other articles:

				B. E. Wisse, K. Ogimoto, J. Tang, M. K. Harris Jr., E. W. Raines, and M. W. Schwartz Evidence that Lipopolysaccharide-Induced Anorexia Depends upon Central, Rather than Peripheral, Inflammatory Signals Endocrinology, November 1, 2007; 148(11): 5230 - 5237. [Abstract] [Full Text] [PDF]

				M. Dehoux, C. Gobier, P. Lause, L. Bertrand, J.-M. Ketelslegers, and J.-P. Thissen IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK-3beta pathways and inhibition of atrogin-1 mRNA Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E145 - E150. [Abstract] [Full Text] [PDF]

				J.N. Gordon, S.R. Green, and P.M. Goggin Cancer cachexia QJM, November 1, 2005; 98(11): 779 - 788. [Abstract] [Full Text] [PDF]

				J N Gordon, T M Trebble, R D Ellis, H D Duncan, T Johns, and P M Goggin Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial Gut, April 1, 2005; 54(4): 540 - 545. [Abstract] [Full Text] [PDF]

				P. Crenn, B. Rakotoanbinina, J.-J. Raynaud, F. Thuillier, B. Messing, and J.-C. Melchior Hyperphagia Contributes to the Normal Body Composition and Protein-Energy Balance in HIV-Infected Asymptomatic Men J. Nutr., September 1, 2004; 134(9): 2301 - 2306. [Abstract] [Full Text] [PDF]

				C. R. PLATA-SALAMAN Cytokine-Induced Anorexia: Behavioral, Cellular, and Molecular Mechanisms Ann. N.Y. Acad. Sci., September 29, 1998; 856(1): 160 - 170. [Abstract] [Full Text] [PDF]